FDA Clears AI Software for Lumbar Spine MRI Analysis
The MSKai software provides AI-powered segmentation, labeling, and measurement tools for assessment of T2-weighted MRIs of the lumbar spine.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MSKai software, which offers a variety of adjunctive artificial intelligence (AI) tools for evaluating lumbar spine magnetic resonance imaging (MRI).
Through assessment of T2-weighted MRI scans of the lumbar spine, the MSKai software provides pathology detection, anatomical segmentation, labeling, and measurements within seconds, according to MSKai, the developer of the software.
For adjunctive assessment of lumbar spine MRIs, the newly FDA-cleared MSKai software provides AI-powered pathology detection, anatomical segmentation and measurements within seconds, according to MSKai, the developer of the software. (Image courtesy of Adobe Stock.)
The company maintained that the MSKai software can facilitate pre-surgical authorizations as well as monitoring of post-intervention treatments.
"The FDA's decision confirms that MSKai meets rigorous safety and performance standards as a spine imaging tool," said Chip Wade, Ph.D., chief operating officer at MSKai. "We're proud to deliver a product that gives healthcare professionals enhanced capabilities in lumbar spine analysis while reinforcing the central role of expert clinical judgement."
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
